Sciclone Pharma (SCLN) Cash Flow Statement

Click line-items for a historical chart and %

Net income	24.32M
Non-cash expense related to stock-based compensation	4.58M
Depreciation and amortization	737K
Realized gain on investments
Other non-cash expense
Liability for contingent consideration
Deferred tax, net	199K
Other long-term liabilities	-8K
Accounts receivable	1.57M
Inventories	641K
Prepaid expenses and other assets	686K
Accounts payable	-2.47M
Accrued and other current liabilities	845K
Deferred revenue
Net cash provided by operating activities
Acquisition of NovaMed, net of cash acquired
Purchases of available-for-sale investments
Proceeds from the sale or maturities of available-for-sale investments
Proceeds from the sale or maturity of trading security investments
Purchases of property and equipment	-141K
Net cash used in investing activities
Proceeds from issuances of common stock
Net cash provided by financing activities
Effect of exchange rate changes on cash and cash equivalents	2K
Net (decrease) increase in cash and cash equivalents	28.71M
Cash and cash equivalents, beginning of period	101.4M
Cash and cash equivalents, end of period	130.11M
Income taxes paid related to foreign operations
Interest and unused line fees paid related to line-of-credit

Entities mentioned with SCLN

View All Entities